NCT03890042

Dienogest for Treatment of Adenomyotic Uteri

Dienogest Versus a Low-dose Combined Oral Contraceptive for Treatment of Adenomyotic Uteri

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Assiut University · Academic / Other
• Sex: Female
• Age: 20 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

Adenomyosis is a common disease in women aged 40-50 years. It associates with dysmenorrhea and menorrhagia. Hysterectomy was considered the main treatment that could definitively cure this disease. Other treatment options are increasingly offered, including hormonal suppression with gonadotropin-releasing hormone agonists or danazol and endometrial ablation. However, deep adenomyosis responds weakly to the above treatment options, which are commonly not considered for long-term management because of the associated side effects. Dienogest is a progestin medication which is used in birth control pills and in the treatment of endometriosis and adenomyosis. Low-dose combined oral contraceptive (COC) pills have been widely used as the primary treatment for menorrhagia. COCs can also be used to induce endometrial atrophy and to decrease endometrial prostaglandin production, which can consequently improve menorrhagia and dysmenorrhea that are associated with adenomyosis

Conditions

• Adenomyosis

Interventions

Type	Name	Description
DRUG	Dienogest group	VISANNE 2MG Tablet once daily
DRUG	Gestodene-Ethinyl Estradiol	Gynera tablet once daily
RADIATION	Ultrasound	ultrasound assessment of uterine volume
OTHER	visual analogue scale	visual analogue scale for assessment of pain

Timeline

• Start date: 2019-03-01
• Primary completion: 2020-07-01
• Completion: 2020-08-01
• First posted: 2019-03-26
• Last updated: 2020-08-25

Locations

1 site across 1 country: Egypt